Publications

Paper

2026

◾ Cho, S.M., Kim, Y.E., Choi, E.H.(2026) Roles of meiotic and mitotic cohesin in stem cell gene regulation and genome stability. Molecular Therapy Nucleic Acids.

◾ Choi, E.H.  (2026) Diverse roles of cohesin in chromosome dynamics and stem cells. BioTech. 10.3390/biotech15030070.

◾ Choi, E.H.  (2026) PRX5 as a redox regulator of STAT3 signaling in cancer stem cells. BioCell. doi.org/10.32604.

◾ Park, S.J., Lee, S.W., Moon, H., Jung, S.M., Kim, J., Lee, D.K. and Choi, E.H.  (2026) Amphiregulin drives EGFR-dependent genome stability in colorectal cancer and represents a targetable vulnerability. Oncogene. s41388-026-03850-5.

◾ Lee, S.W., Park, S.J., Lee, G.E., Lee, J., Yeom, E., Lee, D.K and Choi, E.H.  (2026) PRX5 as a critical driver of colorectal cancer stemness and tumorigenicity. Redox Report. 31(1):2673661. [다음뉴스] [충청타임즈] [뉴스1] [충북일보] 

2025

◾ Kim, Y.E., Park, S.J., Choi, E.H.  (2025) Targeting AREG and EREG to Inhibit Proliferation and Enhance Therapeutic Efficacy in Breast Cancer. J. Biotech. Bioindustry. 13(0):46-51.

◾ Yoon, S., Choi E.H. et al (2025) Biallelic BRF2 mutations disrupt redox homeostasis as etiological factors in syndromic immunodeficiency and developmental disorders. Mol. Ther. 33(11):5661-5680. 

◾ Lee, G.E*., Park, S.J*., Joo, S.M., Choi, E.H. (2025) Recent applications, future perspectives, and limitations of the CRISPR-Cas system. Mol. Ther. Nuc. Acids. 33(11):5661-5680 [세종경제뉴스] [충북일보] [이뉴스투데이] [한국교통대신문] 

◾ Lim J.H*., Choi, E.H*., Kim, Y., Kim, M., Choi D.K., Kim, W. (2025) Identification of YAP regulators through high-throughput screening and NanoBiT-based validation-drug repositioning for cancer therapy. Ani. Cells Syst. 29, 325-388.

◾ Kim K.P, Choi, E.H (2025) Cohesin and condensin regulate chromosome topology and play an essential role in maintaining pluripotency in embryonic stem cells. Sci. Rep. 15, doi: 10.1038/s41598-025-94533-w [한국대학신문] [한국교통대신문] [충청매일] [뉴스원] [충북일보] [대학in] [이뉴스투데이] 

2024

◾ Li, Y., Zhao, C., Zhuang, Z., Moon, U.K., Park, J., Choi, E.H., Min, S., Jiang, G. (2024) Effect of chitooligosaccharide on the binding domain of the SARS-COV-2 receptor. Int. J. Biol. Mac. 278. 

◾ Choi, E.H., Kim, M.H., and Park, S.J* (2024) Targeting Mitochondrial dysfunction and reactive oxygen species for neurodegenerative diseases treatment. Int. J. Mol. Sci. 25, doi: 10.3390/ijms25147952.

◾ Park, S.J., Park S.J., and Choi, E.H (2024) Synergistic combination of RAD51-SCR7 enhances HR-repair system and improves CRISPR-Cas9 genome editing efficiency by preventing R-loop accumulation. Molecular Therapy Nucleic Acids 35, doi: 10.1016/j.omtn.2024. 102274 [청년의사] [메디팜헬스] [전자신문] 

◾ Joo, J.H., Hong, S., Higashide, M.T., Choi, E.H., Yoon, S., Lee, M.S., Kang, H.A., Shinohara, A., Kleckner, N., Kim, K.P. (2024) RPA interacts with Rad52 to promote meiotic crossover and noncrossover recombination. Nucleic Acids Research 52, 3794-3809 

2023

◾ Choi, E.H., Park, S.J. (2023) TXNIP: A key protein in cellular stress response pathway and a potential therapeutic target. Experimental & Molecular Medicine. 55, 1348-1356. [한빛사 논문] [상위피인용논문] [메디파나뉴스] [대구시뉴스] [라포르시안] 

◾ Park, S.J., Yoon, S., Choi, E.H., Hyeon, H., Lee, K., Kim, K.P. (2023) Elevated expression of exogenous RAD51 enhances the CRISPR/Cas9-mediated genome editing efficiency. BMB reports. 56, 102-107. 

◾ Yoon, S., Choi, E.H., Kim, K.P. (2023) The a-kleisin subunits of cohesin preserves the genome integrity of embryonic stem cells. BMB reports. 56, 108-113. 

2022

◾ Koh, Y.E., Choi, E.H., Kim, K.P. (2022) The kleisin subunits of cohesin involve in the fate determination of embryonic stem cells. Mol. Cells. 45, 820-832. 

◾ Choi, E.H., Yoon, S., Koh, Y.E., Hong, T.K., Do, J.T., Lee, B.K., Hahn, Y., Kim, K.P. (2022) Meiosis-specific cohesin complexes display essential and distinct roles in mitotic embryonic stem cell chromosomes. Genome Biology 3;23(1):70. doi: 10.1186/s13059-022-02632. [한빛사논문] [의학신문] [대구광역시뉴스룸] [전자신문] [경북메일] [메디컬투데이] 

2021 ~ 2017

◾ Choi, E.H., Yoon, S., Koh, Y.E., Seo, Y.J., Kim, K.P. (2020) Maintenance of genome integrity and active homologous recombination in embryonic stem cells. Experimental & Molecular Medicine 52, 1220-1229. 

◾ Jin, H*., Lee, B*., Luo, Y., Choi, Y., Choi, E.H., Jin, H., Kim, K.B., Seo, S.B., Kim, Y.H., Lee, H.H., Kim K.P., Lee, K., Bae, J. (2020) FOXL2 directs DNA double-strand break repair pathways by differentially interacting with Ku. Nature Communications, 24, 10.1038/s41467-020-15748-1. 

◾ Choi, E.H., Kim, K.P. (2019) E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Experimental & Molecular Medicine 51, 1-12. 

◾ Choi, E.H., Yoon, S., Kim, K.P. (2018) Combined Ectopic Expression of Homologous Recombination Factors Promotes Embryonic Stem Cell Differentiation. Molecular Therapy 26, 1154-1165. 

◾ Yoon, S., Choi, E.H., Kim, J.W., Kim, K.P. (2018) Structured illumination microscopy imaging reveals localization of replication protein A between chromosome lateral elements during mammalian meiosis. Experimental & Molecular Medicine 50, 1-12. 

◾ Choi, E.H., Yoon, S., Park, K.S., Kim, K.P (2017) The homologous Recombination Machinery Orchestrates Post-replication DNA Repair During Self-renewal of Mouse Embryonic Stem Cells. Scientific Reports, 7, 1-.21 

◾ Choi, E.H., Yoon, S., Hahn, Y., Kim, K.P (2017) Cellular Dynamics of Rad51 and Rad54 in Response to Postreplicative Stress and DNA Damage in HeLa Cells. Molecules and Cells 40, 143-150 

◾ Hong, S., Choi, E.H., Kim, K.P. (2017) Ycs4 is Required for Efficient Double-Strand Break Formation and Homologous Recombination During Meiosis. Journal of Microbiology and Biotechnology 25, 1026-1035

Patent

◾ Moon, U.K., Lee, S., Lee, S.Y., Choi, E.H. Park, J.W., Kim, N.H (2024) Pharmaceutical compositions for the treatment of tuberous sclerosis complex comprising a novel Rheb inhibitor. Apply for patent :1020240170826. (신규 Rheb 활성 억제제를 포함하는 결절성경화증 치료용 약학적 조성물)

◾ Choi, E.H. (2024) Method for improving efficiency of gene editing using CRISPR-Cas9 system. Apply for patent :1020240035589. (CRISPR-Cas9 기반 동시 유전자교정 시스템을 이용한 암 질환 예방 또는 치료방법)

◾ Choi, E.H., Park, S.J. (2024) Establishment of Cancer targeting system using multi-gene editing technologies. Apply for patent :1020240059687. (CRISPR-Cas9 시스템을 이용한 유전자 교정 효율 증진 방법)

◾ Park, S., Choi., E.H., Kim, K.P. (2023) Development of CRISPR-Cas9 vector to genome edit of mammalian cells. Apply for patent: 1020230136479. (동물세포의 유전자 교정을 위한 CRISPR-Cas9 벡터 개발)

◾ Choi, E.H., Yoon, S., Kim, K.P. (2022) Technology for enhancing efficiency of embryonic stem cell differentiation through ectopic expression of REC8 gene. Apply for patent: 1020230116478. (REC8 유전자의 과발현을 통한 배아줄기세포 분화 효율 증진 기술)

◾ Choi, E.H., Yoon, S., Kim, K.P. (2020) Method of promoting stem cell differentiation efficiency. Registration of patent: 1020915110000. (줄기세포 분화 효율 촉진 방법)